UNSPSC 51283607: Rifamycin b

This classification denotes an antitubercular agent with the molecular formula C39H49NO14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8DDB535DJI, chemically known as 4-o-(carboxymethyl)rifamycin, but more generally known as rifamycin b, which bears US NIH Compound Identifier 5459948. European Medicines Agency schedules rifamycin b or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10310MIG. Most nations, for tariff purposes, schedule rifamycin b under HS 29419000.

SMILES: CC1C(C2C3C(CC(C2O)NC(=O)/C(=C\C=C\[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]([C@H](/C=C/O[C@@]4(C(=O)C3C1O4)C)OC)C)OC(=O)C)C)O)C)O)C)/C)OCC(=O)O)O.

UNSPSC 51283607 Rifamycin b is a Commodity code that in recent state and local procurement shows little activity directly aligned with the code's pharmaceutical ingredient scope. The four recent opportunities posted under this code — spanning Florida, Texas, and Minnesota — involve naloxone and safe drug deactivation systems (Seminole County), direct-to-manufacturer prescription programs (Texas HHS), medical and first aid supplies for fire rescue (City of Tampa), and generic multi-source pharmaceuticals and OTC products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations reference rifamycin b or antibiotics specifically. The issuing bodies include county health departments, state health and human services agencies, municipal fire departments, and state cooperative purchasing consortia, but the code assignment appears to be a mismatch with the work actually being procured.

The geographic spread across Florida, Texas, and Minnesota reflects general pharmaceutical and medical-supply procurement activity, but the code shows no recent opportunities for the rifamycin b antibiotic product itself. The Seminole County procurement (IFB 60459723LAS, due July 26, 2026) is for naloxone systems; the City of Tampa procurement (26P00145, due March 13, 2026) is for medical and first aid supplies with an estimated value of $700,000 and a certified Small Local Business Enterprise set-aside; the Texas HHS RFI (HHS0017013, due April 3, 2026) seeks vendor capabilities for direct-to-manufacturer prescription programs; and the Minnesota MMCAP RFP (S1070000015802, due March 26, 2026) targets generic pharmaceuticals and OTC products through authorized wholesalers. State and local procurement under this code does not presently reflect demand for rifamycin b as a discrete product line.